20150423 – US – EASL2015 TG1050
Category: Press release
Transgene Reports First Quarter 2015 Financial Results
20150422 PR US Q1 2015
Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
20150421 AACR 2015_English
Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
20150416 SPA release version EN clean
Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
20150324 FY results 2014 full release_ENG FINAL
Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
18032015_AACR 2015 curtain raiser_EN
Transgene Announces Financial Calendar for 2015
20150107 PR 2015 financial calendar_EN_ver 1
Transgene Announces Third Quarter 2014 Financial Results
266_en
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
261_en
Transgene Reports First Quarter 2014 Financial Results
254_en
